Please assess the completion status of the following clinical trial:

Trial Title: Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).~* Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time~Exclusion criteria:~* Patients who have been registered once in this study (i.e., re-entry of patients is not allowed).~* Patients who are participating in a registry or clinical trial.~* Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto (Type: None): Patient with COPD to received Spiolto

Based on this trial design, predict the completion outcome and termination type (if applicable).